[⁶⁸Ga]Ga-FAP-2286-Synthesis, Quality Control and Comparison with [¹⁸F]FDG PET/CT in a Patient with Suspected Cholangiocellular Carcinoma.

ABSTRACT: [⁶⁸Ga]Ga-FAP-2286 is a new peptide-based radiopharmaceutical for positron-emission tomography (PET) that targets fibroblast activation protein (FAP). This article describes in detail the automated synthesis of [⁶⁸Ga]Ga-FAP-2286 using a commercially available synthesis tool that includes quality control for routine clinical applications. The synthesis was performed using a Scintomics GRP-3V module and a GMP grade ⁶⁸Ge/⁶⁸Ga generator. A minor alteration for transferring the eluate to the module was established, eliminating the need for new method programming. Five batches of [⁶⁸Ga]Ga-FAP-2286 were tested to validate the synthesis. A stability analysis was conducted up to 3 h after production to determine the shelf-life of the finished pr

SUBMITTER: Hormann AA 

PROVIDER: S-EPMC11435094 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature